AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
Log in

NASDAQ:SNSSSunesis Pharmaceuticals Stock Price, Forecast & News

$0.29
-0.03 (-9.09 %)
(As of 07/2/2020 12:43 PM ET)
Add
Compare
Today's Range
$0.28
Now: $0.29
$0.31
50-Day Range
$0.29
MA: $0.42
$0.62
52-Week Range
$0.20
Now: $0.29
$1.13
Volume247,134 shs
Average Volume8.24 million shs
Market Capitalization$32.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More
Sunesis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.01 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.07 million
Book Value$0.14 per share

Profitability

Net Income$-23,330,000.00

Miscellaneous

Employees29
Market Cap$32.40 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

How has Sunesis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Sunesis Pharmaceuticals' stock was trading at $0.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SNSS stock has decreased by 53.8% and is now trading at $0.2909. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sunesis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Sunesis Pharmaceuticals.

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Sunesis Pharmaceuticals.

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The biopharmaceutical company earned $0.12 million during the quarter, compared to analysts' expectations of $0.15 million. View Sunesis Pharmaceuticals' earnings history.

What price target have analysts set for SNSS?

4 Wall Street analysts have issued 12-month target prices for Sunesis Pharmaceuticals' stock. Their forecasts range from $0.50 to $1.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $0.75 in the next twelve months. This suggests a possible upside of 157.8% from the stock's current price. View analysts' price targets for Sunesis Pharmaceuticals.

Has Sunesis Pharmaceuticals been receiving favorable news coverage?

Media stories about SNSS stock have trended very negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sunesis Pharmaceuticals earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Sunesis Pharmaceuticals.

Are investors shorting Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals saw a decrease in short interest in June. As of June 15th, there was short interest totaling 1,080,000 shares, a decrease of 29.9% from the May 31st total of 1,540,000 shares. Based on an average daily volume of 1,590,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.1% of the company's stock are sold short. View Sunesis Pharmaceuticals' Current Options Chain.

Who are some of Sunesis Pharmaceuticals' key competitors?

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SLS International (SLS), QUALCOMM (QCOM), NVIDIA (NVDA), Amarin (AMRN), Exelixis (EXEL), Crispr Therapeutics (CRSP), Micron Technology (MU), Novavax (NVAX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the following people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
  • Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox, Chief Scientific Officer

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $0.29.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $32.40 million and generates $2.07 million in revenue each year. The biopharmaceutical company earns $-23,330,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is www.sunesis.com.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.